Mode
Text Size
Log in / Sign up

Non-hormonal vaginal moisturizer improves vaginal health indices in postmenopausal breast cancer survivorsCan a simple moisturizer help breast cancer survivors with vaginal discomfort?

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider non-hormonal vaginal moisturizers for symptomatic breast cancer survivors, but evidence for clinical benefit is preliminary.

In an open-label randomized clinical trial, 100 postmenopausal women (aged 45-65 years) with breast cancer (stages I-III) who had completed oncological treatment and reported vaginal dryness and/or dyspareunia were assigned to either a non-hormonal vaginal moisturizer used three times per week at night or a vaginal lubricant used during sexual intercourse. The primary outcome was improvement in vaginal health measured by the Vaginal Health Index (VHI), with secondary outcomes including the Vaginal Assessment Scale (VAS), Vulvar Assessment Scale (VuAS), vaginal pH, and Vaginal Maturation Index (VMI).

After 16 weeks of follow-up, the moisturizer group showed statistically significant improvements compared to the lubricant group across several surrogate endpoints: VAS (p = 0.014), VuAS (p = 0.003), VHI (p < 0.0001), and vaginal pH (p = 0.016). No significant between-group difference was found for the VMI (p = 0.213). The study did not report effect sizes, absolute numbers for these outcomes, or data on clinical symptom relief.

Adherence to the moisturizer regimen was high at 85.9%. No serious adverse events were reported. A total of 12 participants discontinued the study (4 in the moisturizer group, 8 in the lubricant group), though adverse event details were not provided. The trial was open-label without a placebo control, using an active comparator (lubricant). Key limitations include the lack of reported effect sizes and absolute outcome numbers, reliance on scale-based surrogate outcomes rather than direct clinical measures, and potential bias from the open-label design.

For clinicians managing postmenopausal breast cancer survivors with vaginal symptoms, this trial provides preliminary evidence that regular use of a non-hormonal vaginal moisturizer may improve certain physiological and self-reported vaginal health indices more than lubricant use alone. However, the absence of placebo comparison, unreported effect magnitudes, and lack of clinical outcome data necessitate cautious interpretation. The findings support considering moisturizers as part of a non-hormonal management strategy, but their superiority for meaningful symptom relief remains uncertain.

Surviving breast cancer is a monumental feat, but for many women, the aftermath includes a deeply personal struggle: vaginal dryness and pain that can make intimacy difficult and daily life uncomfortable. Hormone-based treatments are often off the table, leaving them searching for safe, effective relief.

A new study put a non-hormonal vaginal moisturizer to the test. Researchers asked 100 postmenopausal women who had finished their main cancer treatments to either use the moisturizer three times a week or to use a lubricant only during sex. After 16 weeks, the women using the regular moisturizer saw more improvement. Their scores were better on scales measuring vaginal and vulvar health, and their vaginal pH—a marker of tissue health—decreased more. It's important to note the study didn't measure how big these improvements were in practical terms, or exactly how much better women felt in their daily lives.

The moisturizer was well-tolerated, with high adherence and no serious side effects reported. However, this was an open-label trial, meaning everyone knew which product they were using, which can influence how people report their symptoms. The study compared the moisturizer to a lubricant, not to a placebo (an inactive gel), so we can't say for sure if the moisturizer itself caused the benefits or if the act of applying any product regularly made the difference. For women navigating this challenging side effect, it's a promising signal that a simple, non-hormonal routine might offer meaningful help.

What this means for you:
A regular vaginal moisturizer may improve comfort more than lubricant alone for some breast cancer survivors.

Study Details

Study typeRct
EvidenceLevel 2
Follow-up3.7 mo
PublishedApr 2026
View Original Abstract ↓
OBJECTIVE: To evaluate the effectiveness of non-hormonal vaginal moisturizer on vaginal and vulvar health in postmenopausal women with breast cancer. STUDY DESIGN: A randomized, open-label trial was conducted in women aged 45-65 years with breast cancer (stages I-III) who had completed oncological treatment (excluding endocrine therapy) and reported vaginal symptoms (vaginal dryness and/or dyspareunia). Participants were randomized into two groups: one group used a vaginal moisturizer (three times per week, at night, n = 50) and the other a vaginal lubricant (during sexual intercourse, n = 50). The 16-week intervention included assessments at baseline, 8, and 16 weeks. MAIN OUTCOME MEASURES: Vaginal and vulvar health were assessed using the Vaginal Assessment Scale (VAS), Vulvar Assessment Scale (VuAS), Vaginal Health Index (VHI), vaginal pH, and Vaginal Maturation Index (VMI). The primary outcome was improvement in vaginal health as measured by the VHI. RESULTS: Of the 100 randomized women, 12 discontinued the study (4 in the moisturizer group and 8 in the lubricant group). Adherence to the moisturizer was high (85.9%) and no serious adverse events were reported. At 8 and 16 weeks, the moisturizer group showed significant improvement in VAS (p = 0.014) and VuAS (p = 0.003) scores, as well as a significant increase in VHI scores, indicating improvements in elasticity, moisture, fluid volume, epithelial integrity, and pH (p < 0.0001) compared with the control group. Vaginal pH significantly decreased in the moisturizer group compared with the control group (p = 0.016). No significant between-group differences were observed in VMI scores after 16 weeks (p = 0.213). CONCLUSIONS: The non-hormonal vaginal moisturizer was effective in improving vaginal and vulvar health parameters in postmenopausal women with breast cancer compared with a vaginal lubricant. Brazilian Clinical Trials Registry (ReBEC,) number RBR-5cf7vzj.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.